Tc 99m duramycin

Drug Profile

Tc 99m duramycin

Alternative Names: Tc-99m-duramycin; Technetium 99m duramycin; Technetium duramycin

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical College of Wisconsin
  • Developer Molecular Targeting Technologies
  • Class Cardiovascular therapies; Heavy metals; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cardiovascular disorders; Inflammation

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 29 Jul 2015 Tc 99m duramycin is available for licensing in World as of 29 Jul 2015.
  • 15 May 2015 Preclinical trials in Cancer (Diagnosis) in USA (IV)
  • 15 May 2015 Preclinical trials in Cardiovascular disorders (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top